From concept to potential therapeutics: Neuroprotective peptides

Handbook of Neurochemistry and Molecular Neurobiology: Neural Protein Metabolism and Function

Volumn , Issue , 2007, Pages 673-688

  Gozes, I ^a,b   Tiong, J ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b Allon Therapeutics   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79958179195     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-30379-6_24     Document Type: Chapter

References (95)

1. Alcalay RN, Giladi E, Pick CG, Gozes I. 2004. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett 361:128-131.
2. Ashur-Fabian O, Perl O, Lilling G, Fridkin M, Gozes I. 1999. SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival. Peptides 20:629-633.
3. Ashur-Fabian O, Segal-Ruder Y, Skutelsky E, Brenneman DE, Steingart RA, et al. 2003. The neuroprotective peptide NAP inhibits the aggregation of the β-amyloid peptide. Peptides 24:1413-1423.
4. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, et al. 1999. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 72:1283-1293.
5. Bassan M, Zamostiano R, Giladi E, Davidson A, Wollman Y, et al. 1998. The identification of secreted heat shock 60-like protein from rat glial cells and a human neuroblastoma cell line. Neurosci Lett 250:37-40.
6. Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart RA, et al. 2001. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J Pharmacol Exp Ther 296:57-63.
7. Blondel O, Collin C, McCarran WJ, Zhu S, Zamostiano R, et al. 2000. A glia-derived signal regulating neuronal differentiation. J Neurosci 20:8012-8020.
8. Brenneman DE, Eiden LE. 1986. Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc Natl Acad Sci USA 83:1159-1162.
9. Brenneman DE, Gozes I. 1996. A femtomolar-acting neuroprotective peptide. J Clin Invest 97:2299-2307.
10. Brenneman DE, Glazner G, Hill JM, Hauser J, Davidson A, et al. 1998a. VIP neurotrophism in the central nervous system: Multiple effectors and identification of a femtomolar-acting neuroprotective peptide. Ann N Y Acad Sci 865:207-212.
11. Brenneman DE, Hauser J, Neale E, Rubinraut S, Fridkin M, et al. 1998b. Activity-dependent neurotrophic factor: Structure-activity relationships of femtomolar-acting peptides. J Pharmacol Exp Ther 285:619-627.
12. Brenneman DE, Spong CY, Gozes I. 2000. Protective peptides derived from novel glial proteins. Biochem Soc Trans 28:452-455.
13. Brenneman DE, Spong CY, Hauser JM, Abebe D, Pinhasov A, et al. 2004. Protective peptides that are orally active and mechanistically nonchiral. J Pharmacol Exp Ther 309:1190-1197.
14. Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, et al. 1988. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 335:639-642.
15. Busciglio J, Lorenzo A, Yeh J, Yankner BA. 1995. β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14:879-888.
16. Busciglio J, Relsman A, Helguera P, Ashur-Fabian O, Pinsahov A, et al. (In Press). NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. Curr Pharm Des
17. Cash AD, Aliev G, Siedlak SL, Nunomura A, Fujioka H, et al. 2003. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol 162:1623-1627.
18. Chiba T, Hashimoto Y, Tajima H, Yamada M, Kato R, et al. 2004. Neuroprotective effect of activity-dependent neurotrophic factor against toxicity from familial amyotrophic lateral sclerosis-linked mutant SOD1 in vitro and in vivo. J Neurosci Res 78:542-552.
19. Divinski I, Mittelman L, Gozes I. 2004. A femtomolar-acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 279:28531-28538.
20. Ferreira A, Lu Q, Orecchio L, Kosik KS. 1997. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A β. Mol Cell Neurosci 9:220-234.
21. Furman S, Hill JM, Vulih I, Zaltzman R, Hauser JM, et al. 2005. Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neurosci Lett 373:73-78.
22. Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE. 2004. Subcellular localization and secretion of activitydependent neuroprotective protein in astrocytes. Neuron Glia Biol 1:193-199.
23. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, et al. 1998. Aging renders the brain vulnerable to amyloid-β protein neurotoxicity. Nat Med 4:827-831.
24. Glowa JR, Panlilio LV, Brenneman DE, Gozes I, Fridkin M, et al. 1992. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res 570:49-53.
25. Gozes I, Brenneman DE. 1989. VIP: Molecular biology and neurobiological function. Mol Neurobiol 3:201-236.
26. Gozes I, Brenneman DE. 1993. Neuropeptides as growth and differentiation factors in general and VIP in particular. J Mol Neurosci 4:1-9.
27. Gozes I, Brenneman DE. 1996. Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? J Mol Neurosci 7:235-244.
28. Gozes I, Brenneman DE. 2000. A new concept in the pharmacology of neuroprotection. J Mol Neurosci 14:61-68.
29. Gozes I, Divinski I. 2004. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. J Alzheimers Dis 6:S37-41.
30. Gozes I, Fridkin M. 1992. A fatty neuropeptide. Potential drug for noninvasive impotence treatment in a rat model. J Clin Invest 90:810-814.
31. Gozes I, Furman S. 2004. Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update. Best Pract Res Clin Endocrinol Metab 18:623-640.
32. Gozes I, Littauer UZ. 1982. Microtubule protein: Tubulin. Scand J Immunol Suppl 9:299-316.
33. Gozes I, Alcalay R, Giladi E, Pinhasov A, Furman S, et al. 2002. NAP accelerates the performance of normal rats in the water maze. J Mol Neurosci 19:167-170.
34. Gozes I, Avidor R, Biegon A, Baldino F Jr. 1989. Lactation elevates vasoactive intestinal peptide messenger ribonucleic acid in rat suprachiasmatic nucleus. Endocrinology 124:181-186.
35. Gozes I, Bachar M, Bardea A, Davidson A, Rubinraut S, et al. 1997a. Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: Implications for early treatment of Alzheimer's disease. J Neurobiol 33:329-342.
36. Gozes I, Bachar M, Bardea A, Davidson A, Rubinraut S, et al. 1998. Protection against developmental deficiencies by a lipophilic VIP analogue. Neurochem Res 23:689-693.
37. Gozes I, Bardea A, Bechar M, Pearl O, Reshef A, et al. 1997b. Neuropeptides and neuronal survival: Neuroprotective strategy for Alzheimer's disease. Ann N Y Acad Sci 814:161-166.
38. Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, et al. 1996a. Neuroprotective strategy for Alzheimer's disease: Intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci USA 93:427-432.
39. Gozes I, Davidson A, Gozes Y, Mascolo R, Barth R, et al. 1997c. Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: Immunological and biological specificity. Brain Res Dev Brain Res 99:167-175.
40. Gozes I, Fridkin M, Hill JM, Brenneman DE. 1999. Pharmaceutical VIP: Prospects and problems. Curr Med Chem 6:1019-1034.
41. Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE. 2000a. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther 293:1091-1098.
42. Gozes I, Glowa J, Brenneman DE, McCune SK, Lee E, et al. 1993. Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene. J Mol Neurosci 4:185-193.
43. Gozes I, Lilling G, Davidson A, Bardea A, Reshef A, et al. 1996b. Development of VIP agonists and antagonists with tissue and receptor specificity: Effects on behavioral maturation, sexual function, and the biologic clock. Ann N Y Acad Sci 805:159-169; discussion 169-171.
44. Gozes I, Lilling G, Glazer R, Ticher A, Ashkenazi IE, et al. 1995. Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J Pharmacol Exp Ther 273:161-167.
45. Gozes I, McCune SK, Jacobson L, Warren D, Moody TW, et al. 1991. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J Pharmacol Exp Ther 257:959-966.
46. Gozes I, Schachter P, Shani Y, Giladi E. 1988. Vasoactive intestinal peptide gene expression from embryos to aging rats. Neuroendocrinology 47:27-31.
47. Gozes I, Shani Y, Rostene WH. 1987. Developmental expression of the VIP gene in brain and intestine. Brain Res 388:137-148.
48. Gozes I, Vulih I, Spivak-Pohis I, Furman S. 2005a. Neuroendocrine aspects of molecular chaperones: ADNF and ADNP. Henderson B, Packley AG, eds. Molecular chaperones and cell signalling. Cambridge University Press. pp. 251-262.
49. Gozes I, Zaltzman R, Giladi E, Grigoriadis N, Brenneman D, et al. 2003. Treatment of experimental encephalomyelitis by intranasal application of ADNP peptide, NAP. Program No 9521. Abstract Viewer/Itinerary Planner Washington, DC: Society for Neuroscience.
50. Gozes I, Zaltzman R, Hauser J, Brenneman D. E, Shohami E, et al. 2005b. The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP-derived peptide, NAP, reduces the severity of traumatic head injury. Current Alzheimer's Research. 2:149-153.
51. Gozes I, Zamostiano R, Pinhasov A, Bassan M, Giladi E, et al. 2000b. A novel VIP responsive gene. Activity-dependent neuroprotective protein. Ann N Y Acad Sci 921:115-118.
52. Gressens P, Besse L, Robberecht P, Gozes I, Fridkin M, et al. 1999. Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives. J Pharmacol Exp Ther 288:1207-1213.
53. Gressens P, Hill JM, Gozes I, Fridkin M, Brenneman DE. 1993. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 362:155-158.
54. Gressens P, Hill JM, Paindaveine B, Gozes I, Fridkin M, et al. 1994. Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J Clin Invest 94:2020-2027.
55. Gressens P, Marret S, Hill JM, Brenneman DE, Gozes I, et al. 1997. Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J Clin Invest 100:390-397.
56. Guo Q, Sebastian L, Sopher BL, Miller MW, Glazner GW, et al. 1999. Neurotrophic factors (activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)) interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc Natl Acad Sci USA 96:4125-4130.
57. Hashimoto Y, Kaneko Y, Tsukamoto E, Frankowski H, Kouyama K, et al. 2004. Molecular characterization of neurohybrid cell death induced by Alzheimer's amyloid-b peptides via p75NTR/PLAIDD. J Neurochem 90:549-558.
58. Ho AK, Chik CL, Klein DC. 1987. Transmembrane receptor cross-talk: Concurrent VIP and α1-adrenergic activation rapidly elevates pinealocyte cGMP greater than 100-fold. Biochem Biophys Res Commun 146:1478-1484.
59. Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, et al. 1999. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24:751-762.
60. Khan IU, Wallin R, Gupta RS, Kammer GM. 1998. Protein kinase A-catalyzed phosphorylation of heat shock protein 60 chaperone regulates its attachment to histone 2B in the T lymphocyte plasma membrane. Proc Natl Acad Sci USA 95:10425-10430.
61. Lagreze WA, Pielen A, Steingart R, Schlunck G, Hofmann HD, et al. 2005. The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci 46:933-938.
62. Lee VM, Goedert M, Trojanowski JQ. 2001. Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121-1159.
63. Leker RR, Teichner A, Grigoriadis N, Ovadia H, Brenneman DE, et al. 2002. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke 33:1085-1092.
64. Magistretti PJ, Schorderet M. 1984. VIP and noradrenaline act synergistically to increase cyclic AMP in cerebral cortex. Nature 308:280-282.
65. Maness LM, Kastin AJ, Weber JT, Banks WA, Beckman BS, et al. 1994. The neurotrophins and their receptors: Structure, function, and neuropathology. Neurosci Biobehav Rev 18:143-159.
66. Michaelis ML, Ansar S, Chen Y, Reiff ER, Seyb KI, et al. 2004. βAmyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. J Pharmacol Exp Ther 48:832-838.
67. Morfini G, Pigino G, Beffert U, Busciglio J, Brady ST. 2002. Fast axonal transport misregulation and Alzheimer's disease. Neuromolecular Med 2:89-99.
68. Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, et al. 2000. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: Relevance to neuroprotection in Parkinson's disease. Brain Res 854:257-262.
69. Ogiwara T, Murdoch G, Chik CL, Ho AK. 1995. Tyrosine kinase inhibitors enhance cGMP production in rat pinealocytes. Biochem Biophys Res Commun 207:994-1002.
70. Patterson PH. 1992. The emerging neuropoietic cytokine family: first CDF/LIF, CNTF, and IL-6; next ONC, MGF, GCSF? Curr Opin Neurobiol 2:94-97.
71. Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, et al. 2003. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res 144:83-90.
72. Poggi SH, Goodwin K, Hill JM, Brenneman DE, Tendi E, et al. 2003. The role of activity-dependent neuroprotective protein in a mouse model of fetal alcohol syndrome. Am J Obstet Gynecol 189:790-793.
73. Poggi SH, Vink J, Goodwin K, Hill JM, Brenneman DE, et al. 2002. Differential expression of embryonic and maternal activity-dependent neuroprotective protein during mouse development. Am J Obstet Gynecol 187:973-976.
74. Romano J, Beni-Adani L, Nissenbaum OL, Brenneman DE, Shohami E, et al. 2002. A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: Gene atlas array analysis. J Mol Neurosci 18:37-45.
75. Said SI. 1991. Vasoactive intestinal polypeptide (VIP) in asthma. Ann N YAcad Sci 629:305-318.
76. Said SI, Mutt V. 1970. Polypeptide with broad biological activity: I solation from small intestine. Science 169:1217-1218.
77. Schaad NC, Vanecek J, Rodriguez IR, Klein DC, Holtzclaw L, et al. 1995. Vasoactive intestinal peptide elevates pinealocyte intracellular calcium concentrations by enhancing influx: Evidence for involvement of a cyclic GMP-dependent mechanism. Mol Pharmacol 47:923-933.
78. Sigalov E, Fridkin M, Brenneman DE, Gozes I. 2000. VIP-related protection against iodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury. J Mol Neurosci 15:147-154.
79. Sigurdsson EM, Lee JM, Dong XW, Hejna MJ, Lorens SA. 1997. Bilateral injections of amyloid-b25-35 into the amygdala of young Fischer rats: Behavioral, neurochemical, and time-dependent histopathological effects. Neurobiol Aging 18:591-608.
80. Smith-Swintosky VL, Gozes I, Brenneman DE, D'Andrea MR, Plata-Salaman CR. 2005. Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci 25:225-238.
81. Spong CY, Abebe DT, Gozes I, Brenneman DE, Hill JM. 2001. Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. J Pharmacol Exp Ther 297:774-779.
82. Steingart RA, Solomon B, Brenneman DE, Fridkin M, Gozes I. 2000. VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. J Mol Neurosci 15:137-145.
83. Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, et al. 2004. Oligomerization of Alzheimer's βamyloid within processes and synapses of cultured neurons and brain. J Neurosci 24:3592-3599.
84. White DM, Walker S, Brenneman DE, Gozes I. 2000. CREB contributes to the increased neurite outgrowth of sensory neurons induced by vasoactive intestinal polypeptide and activity-dependent neurotrophic factor. Brain Res 868:31-38.
85. Wilkemeyer MF, Chen SY, Menkari CE, Brenneman DE, Sulik KK, et al. 2003. Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity. Proc Natl Acad Sci USA 100:8543-8548.
86. Wilkemeyer, MF, Chen, SY, Menkari, CE, Sulik, KK, Charness, ME. 2004. Ethanol antagonist peptides: Structural specificity without stereospecificity. J Pharmacol Exp Ther 309:1183-1189.
87. Wilkemeyer MF, Menkari CE, Spong CY, Charness ME. 2002. Peptide antagonists of ethanol inhibition of L1-mediated cell-cell adhesion. J Pharmacol Exp Ther 303:110-116.
88. Wu JY, Henins KA, Gressens P, Gozes I, Fridkin M, et al. 1997. Neurobehavioral development of neonatal mice following blockade of VIP during the early embryonic period. Peptides 18:1131-1137.
89. Zaltzman R, Alexandrovich A, Beni SM, Trembovler V, Shohami E, et al. 2004. Brain injury-dependent expression of activity-dependent neuroprotective protein. J Mol Neurosci 24:181-187.
90. Zaltzman R, Alexandrovich A, Trembolver V, Shohami E, Gozes, I. 2005. The influence of the peptide NAP on Mac-1-deficient mice following closed head injury. Peptides. 26:1520-1527.
91. Zamostiano R, Pinhasov A, Bassan M, Perl O, Steingart RA, et al. 1999. A femtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: a potential neuroprotective mechanism. Neurosci Lett 264:9-12.
92. Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, et al. 2001. Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem 276:708-714.
93. Zemlyak I, Furman S, Brenneman DE, Gozes I. 2000. A novel peptide prevents death in enriched neuronal cultures. Regul Pept 96:39-43.
94. Zhou FC, Sari Y, Powrozek TA, Spong CY. 2004. A neuroprotective peptide antagonizes fetal alcohol exposurecompromised brain growth. J Mol Neurosci 24:189-199.
95. Zusev M, Gozes I. 2004. Differential regulation of activitydependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul Pept 123:33-41.